Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease.
Nat Nanotechnol
; 13(9): 812-818, 2018 09.
Article
in En
| MEDLINE
| ID: mdl-29988049
ABSTRACT
Though emerging evidence indicates that the pathogenesis of Parkinson's disease is strongly correlated to the accumulation1,2 and transmission3,4 of α-synuclein (α-syn) aggregates in the midbrain, no anti-aggregation agents have been successful at treating the disease in the clinic. Here, we show that graphene quantum dots (GQDs) inhibit fibrillization of α-syn and interact directly with mature fibrils, triggering their disaggregation. Moreover, GQDs can rescue neuronal death and synaptic loss, reduce Lewy body and Lewy neurite formation, ameliorate mitochondrial dysfunctions, and prevent neuron-to-neuron transmission of α-syn pathology provoked by α-syn preformed fibrils5,6. We observe, in vivo, that GQDs penetrate the blood-brain barrier and protect against dopamine neuron loss induced by α-syn preformed fibrils, Lewy body/Lewy neurite pathology and behavioural deficits.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Parkinson Disease
/
Blood-Brain Barrier
/
Quantum Dots
/
Alpha-Synuclein
/
Protein Aggregation, Pathological
/
Graphite
Limits:
Animals
/
Humans
Language:
En
Journal:
Nat Nanotechnol
Year:
2018
Document type:
Article
Affiliation country:
Estados Unidos